AbbVie, a firm that researches and develops pharmaceutical products, agreed to acquire Mitokinin, a developer of kinase-targeted neo-substrates intended to treat neurodegenerative and mitochondrial diseases. Financial terms were not disclosed. "It's a testament to the quality of our science and the strength of our scientific team that we were able to attract a partner of AbbVie's caliber. I'm excited to continue to demonstrate the therapeutic potential of our specific PINK1 targeting compounds and to push towards the clinic with the AbbVie team," Nicholas Hertz, Mitokinin Co-Founder and CSO.